Home・Aktien・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Geschlossen

BrancheGesundheitswesen

74.54 -1

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

74.01

Max

75.29

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M -156M
Verkäufe	28M 222M
EPS	-0.78
Gewinnspanne	-70.082
Angestellte	999
EBITDA	-24M -137M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+45.13% upside

Dividenden
By Acuity
Nächstes Ergebnis	28. Okt. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-1.6B 15B
Vorheriger Eröffnungskurs	75.54
Vorheriger Schlusskurs	74.54

Nachrichtenstimmung

By Acuity

27%

73%

70 / 339 Ranking in Healthcare

Bridgebio Pharma Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Sept. 2026, 19:36 UTC

Social Media

News

Event

BridgeBio Pharma will present new infigratinib data at a pediatric endocrinology meeting in September. HC Wainwright maintains a Buy rating and $120 price target.

1. Sept. 2026, 23:16 UTC

News

BridgeBio Pharma shares are lower in after-market hours following a $500 million mixed securities shelf filing, raising concerns about potential dilution.

28. Aug. 2026, 20:08 UTC

Social Media

BridgeBio Pharma Inc's shares are lower today, continuing a downward trend despite positive social media discussions regarding its treatment, Attruby, based on WF's analysis.

20. Aug. 2026, 19:46 UTC

Correlated Moves

Shares lower amid broader biotechnology sector decline.

19. Aug. 2026, 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

18. Aug. 2026, 20:06 UTC

Social Media

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

14. Aug. 2026, 20:06 UTC

Social Media

News

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

13. Aug. 2026, 23:01 UTC

News

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

12. Aug. 2026, 19:51 UTC

News

Social Media

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

11. Aug. 2026, 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

10. Aug. 2026, 23:21 UTC

News

Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

7. Aug. 2026, 20:03 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6. Aug. 2026, 19:16 UTC

Social Media

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5. Aug. 2026, 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4. Aug. 2026, 19:36 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3. Aug. 2026, 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31. Juli 2026, 19:56 UTC

Correlated Moves

Social Media

BBIO shares decline, continuing a three-day trend amid sector weakness.

30. Juli 2026, 20:21 UTC

Correlated Moves

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29. Juli 2026, 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

28. Juli 2026, 19:07 UTC

Correlated Moves

BBIO shares lower today amid declining biotech sector sentiment.

27. Juli 2026, 18:26 UTC

Social Media

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.

Peer-Vergleich

Kursveränderung

Bridgebio Pharma Inc Prognose

Kursziel

By TipRanks

45.13% Vorteil

12-Monats-Prognose

Durchschnitt 109.44 USD 45.13%

Hoch 157 USD

Tief 94 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bridgebio Pharma Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

17 ratings

Buy

Halten

Sell

Basierend auf 17 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Bridgebio Pharma Inc – Dist abgegeben haben.

Stimmung

By Acuity

70 / 339 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.